<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01757067</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00053625</org_study_id>
    <nct_id>NCT01757067</nct_id>
  </id_info>
  <brief_title>Early Elimination of Premature Ventricular Contractions in Heart Failure</brief_title>
  <acronym>EVAC-HF</acronym>
  <official_title>EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ventricular contractions (PVC) are a very common irregular heart beat (arrhythmias)&#xD;
      even in patients without heart disease. Frequent PVCs are thought to occur in about 1-4% of&#xD;
      the general population. Many patients with PVCs complain about skipping of their heart&#xD;
      (palpitations), shortness of breath and feeling tired. In some patients PVCs may also result&#xD;
      in weakening of the heart muscle (heart failure), which might be reversible with suppression&#xD;
      of the PVCs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common way to get rid of PVCs is an ablation procedure during which a small area of heart&#xD;
      muscle that creates the PVCs is cauterized, so that it can no longer cause PVCs. This has&#xD;
      been performed for many years and is an overall safe and effective procedure to eliminate&#xD;
      PVCs. In the ablation, a catheter with an electrode at its tip is guided with moving X-rays&#xD;
      (fluoroscopy) displayed on a video screen to the exact site inside the heart where cells give&#xD;
      off the electrical signals that stimulate the abnormal heart rhythm. Radiofrequency energy&#xD;
      (similar to microwave heat) is transmitted from the catheter tip to the area. This destroys&#xD;
      carefully selected heart muscle cells in a very small area (about 1/5 of an inch) and can&#xD;
      stop the area from creating the extra impulses that cause the extra heartbeats. Additionally,&#xD;
      some medications have the ability to suppress PVCs (antiarrhythmic medications). PVC ablation&#xD;
      and antiarrhythmic medications have both been used to treat patients with PVC's and a reduced&#xD;
      heart function. The heart function is referred to as ejection fraction (measured by cardiac&#xD;
      ultrasound (echocardiogram). In this study it will be required the ejection fraction will be&#xD;
      less than less than or equal to 45% (with 55% or more being normal).&#xD;
&#xD;
      If enrolled in the study there is a 50/50 chance (like a coin toss and referred to as&#xD;
      randomization) that the patient will either continue on the best currently available medical&#xD;
      treatment for a weak heart muscle (as determined by the doctor) or will undergo a PVC&#xD;
      catheter ablation (with a possible second ablation or antiarrhythmic medication, if the first&#xD;
      ablation was not a success).&#xD;
&#xD;
      All patients in the study will continue to take the best possible medications for the heart&#xD;
      muscle weakness. If the patient is randomized to not undergo the ablation they will be&#xD;
      monitored and at the end of 6 months of participation may choose to have the PVC ablation. If&#xD;
      a deterioration may occur patients in the control group can have an ablation earlier.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit sufficient participants&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Left Ventricular Ejection Fraction Measured With Simpson's Rule Expressed in Percent From Pre to Post Intervention</measure>
    <time_frame>Change between 0 and 6 months</time_frame>
    <description>Left ventricular ejection fraction with Simpson's Rule. This is a measurement obtained on an echocardiogram. It reflects the percentage of blood that is ejected from the heart with each beat. The mean change in ejection fraction will be compared for the 2 groups</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Premature Ventricular Contractions</condition>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>ablation procedure vs medical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PVC ablation vs medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compare 2 arms for safety, symptoms</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Compare control of PVC's between 2 groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PVC ablation</intervention_name>
    <description>This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated</description>
    <arm_group_label>ablation procedure vs medical therapy</arm_group_label>
    <other_name>Surround Flow ablation catheters- Biosense Webster</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with reduced ejection fraction (EF â‰¤45%) demonstrated by transthoracic&#xD;
             echocardiogram and deemed to be non-ischemic by nuclear stress test or cardiac&#xD;
             catheterization.&#xD;
&#xD;
          -  Patients with &gt;20% PVCs on 24 hour holter-recording&#xD;
&#xD;
          -  Patient is 18 years of age or older&#xD;
&#xD;
          -  Optimized medical therapy on stable therapy for minimum 3 months with no changes in&#xD;
             beta-blocker, ACE-I/ARB, digoxin doses (varying diuretic doses permitted).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are under the age of 18 years of age&#xD;
&#xD;
          -  Patients with &gt;2 dominant PVC morphologies&#xD;
&#xD;
          -  Patients with cardiac surgery in previous 3 months or scheduled for following 6 months&#xD;
&#xD;
          -  Patients who were implanted with a biventricular device during the last three months&#xD;
             or single/dual chamber device (with ventricular pacing &gt;10%) during the last three&#xD;
             months&#xD;
&#xD;
          -  Significant symptoms associated with PVCs that would make favor immediate ablation&#xD;
&#xD;
          -  Intracardiac mural thrombus or myxoma&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timm Dickfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University maryland medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1252</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Quebec</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 3, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <results_first_submitted>May 15, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2021</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Timm-Michael Dickfeld</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ablations</keyword>
  <keyword>CHF</keyword>
  <keyword>PVC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 17, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01757067/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01757067/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT01757067/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PVC Ablation Plus Optimal Medical Therapy</title>
          <description>Patients will receive optimal medical therapy including beta blocker or afterload reduction with e.g. ACE-inhibitors as directed by treating local cardiologist/electrophysiologist.&#xD;
In addition patient will undergo radiofrequency ablation of PVC guided by current gold standard of ablation including pace mapping and activation mapping to reduce the PVC burden.</description>
        </group>
        <group group_id="P2">
          <title>Optimal Medical Therapy</title>
          <description>Patients will receive optimal medical therapy including beta blocker or afterload reduction with e.g. ACE-inhibitors as directed by treating local cardiologist/electrophysiologist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1">The study was closed due to low enrollment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">The study was closed due to low enrollment.</participants>
                <participants group_id="P2" count="1">The study was closed due to low enrollment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The site enrolled 3 participants in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Ablation Procedure</title>
          <description>Patient received PVC ablation in addition to optimal medical therapy</description>
        </group>
        <group group_id="B2">
          <title>Medical Therapy</title>
          <description>Optimal medical therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="3"/>
                    <measurement group_id="B2" value="68" spread="0"/>
                    <measurement group_id="B3" value="67" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Left Ventricular Ejection Fraction Measured With Simpson's Rule Expressed in Percent From Pre to Post Intervention</title>
        <description>Left ventricular ejection fraction with Simpson's Rule. This is a measurement obtained on an echocardiogram. It reflects the percentage of blood that is ejected from the heart with each beat. The mean change in ejection fraction will be compared for the 2 groups</description>
        <time_frame>Change between 0 and 6 months</time_frame>
        <population>Due to very low enrollment and closure of study no meaningful statistical analysis could be performed</population>
        <group_list>
          <group group_id="O1">
            <title>Ablation Procedure</title>
            <description>PVC ablation will be performed in these patients in addition to optimal medical therapy.</description>
          </group>
          <group group_id="O2">
            <title>Optimal Medical Therapy</title>
            <description>group received only optimal medical therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Left Ventricular Ejection Fraction Measured With Simpson's Rule Expressed in Percent From Pre to Post Intervention</title>
          <description>Left ventricular ejection fraction with Simpson's Rule. This is a measurement obtained on an echocardiogram. It reflects the percentage of blood that is ejected from the heart with each beat. The mean change in ejection fraction will be compared for the 2 groups</description>
          <population>Due to very low enrollment and closure of study no meaningful statistical analysis could be performed</population>
          <units>Percentage of EF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="5"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The previously stated primary and secondary endpoints cannot be calculated as the study was halted prematurely due to lack of enrollment. Only the reported EF data was collected. This makes further statistical analyses impossible.</non_inferiority_desc>
            <other_analysis_desc>The previously stated primary and secondary endpoints cannot be calculated as the study was halted prematurely due to lack of enrollment. Only the reported EF data was collected. This makes further statistical analyses impossible.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>0 to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ablation Procedure and Optimal Medical Therapy</title>
          <description>In the group that received PVC ablation and optimal medical therapy no AE occured.</description>
        </group>
        <group group_id="E2">
          <title>Optimal Medical Therapy</title>
          <description>In the group that received optimal medical therapy no AE occured</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Timm-Michael Dickfeld</name_or_title>
      <organization>University of Maryland Medical Center</organization>
      <phone>410-328-7801</phone>
      <email>Tdickfel@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

